A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?

A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?

Over the last decades, a revolution has occurred in oncology with the development of immune checkpoint inhibitors (ICIs). Following tremendous successes in solid tumors, interest has risen to explore these inhibitors in hematologic malignancies; while Hodgkin's lymphoma (HL) has shown overwhelm...

Full description

Bibliographic Details
Main Authors: Zeinab Davoodi-Moghaddam, Farideh Jafari-Raddani, Maryam Noori, Davood Bashash
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Translational Oncology
Subjects:
Immune checkpoint inhibitor
Immunotherapy
Non-Hodgkin lymphoma
PD-1
PD-L
CTLA-4
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523323000220

Similar Items

Similar Items